| Literature DB >> 22855380 |
B Palmieri1, T Iannitti, G Fistetto, V Rottigni.
Abstract
Outpatient laser ablation of palatine tonsils is a very interesting procedure that has been recently introduced as a routine in head and neck surgery departments. The aim of this study was to describe a new strategy using a Doppler-guided fibre optic neodymium-yttrium-aluminium-garnet (YAG) laser to remove up to 80 % of tonsillar tissue, as assessed in the long-term postoperative clinical evaluation of the volume of the tonsils at the follow-up, and leaving the capsule in place, thus avoiding any haemorrhagic complication and minimize pain. A total of 20 patients (men, n=13; women, n=7), aged between 6 and 63, were recruited for the procedure. They were affected by chronic hypertrophic tonsillitis with a recurrent fever and other symptoms that were related to oral inflammation. Among the 20 patients, no serious adverse events, including haemorrhage-related complications, were observed. Treatment was well tolerated, even in patients displaying an overall low pain threshold. No dropout or uncompleted procedure occurred in the present study. Minor complications included sore throat, moderate oedema, mild acute pharynx inflammation, slight peritonsillar exudate and local burning. The postoperative pain, measured by Scott-Huskisson visual analogue scale, was between 5 and 40 mm and was easily counteracted by means of external ice packages and nonsteroidal anti-inflammatory drugs, according to the individual patient's need. During the 12-36-month follow-up patients showed improved symptoms (n=7) and complete recovery (n=13). A relapse episode was observed in two patients. This study supports fibre optic laser neodymium-YAG tonsil surgery, named "cribriform intracapsular tonsillectomy" or "Swiss-cheese laser tonsillectomy", as an effective alternative to the traditional cold knife approach or electrosurgery. This approach could become the gold standard for tonsil surgery in the third millennium for safety reasons, acceptable cost-benefit ratio, the precise targeting of the beam across the affected tissues and the short- and long-term recovery.Entities:
Mesh:
Year: 2012 PMID: 22855380 PMCID: PMC3637894 DOI: 10.1007/s10103-012-1140-1
Source DB: PubMed Journal: Lasers Med Sci ISSN: 0268-8921 Impact factor: 3.161
Fig. 1Patient undergoing laser tonsillectomy
Fig. 2Patient’s examination the day after laser tonsillectomy
Fig. 3Laser device (Elettronica Valseriana, Bergamo, Italy)
Summary of study results
| Patient number | Age | Diagnosis | Sessions* | Adverse events | Postoperative pain (VAS, mm) measured in the 7 days following the first session (medication used) | Follow-up** |
|---|---|---|---|---|---|---|
| 1 | 24 | Chronic tonsillitis | 1 | / | 20 | 24 months/Improved symptoms |
| 2 | 57 | Hypertrophic tonsillitis | 2 | Moderate sore throat | 10 | 18 months/Complete recovery |
| 3 | 34 | Recurrent tonsillitis | 3 | Moderate burning and local swelling persisting for 24 h | 20 | 36 months/Complete recovery |
| 4 | 37 | Chronic pharyngotonsillitis | 3 | / | 25 | 16 months/Improved symptoms |
| 5 | 26 | Relapsing acute tonsillitis | 1 | / | 5 | 21 months/Complete recovery |
| 6 | 27 | Tonsil remnants with infections | 2 | / | 15 | 24 months/Complete recovery |
| 7 | 24 | Tonsillar hypertrophy and infections | 1 | Moderate oedema | 20 | 16 months/Complete recovery |
| 8 | 56 | Recurrent tonsillitis | 1 | Moderate burning persisting for 48 h | 40 (Diclofenac 100 mg capsules [2 times/day for 3 days; IBSA, Lugano, Switzerland]) | 21 months/Complete recovery |
| 9 | 21 | Relapsing tonsillitis and tonsillar hypertrophy | 1 | Moderate exudate | 30 (Naprosyn 750 mg capsules, [2 times/day for 3 days; Recordati, Italy]) | 20 months/Complete recovery |
| 10 | 6 | Tonsillar hypertrophy | 2 | Moderate pain and dysphagia | 20 (ice) | 24 months /Complete recovery |
| 11 | 32 | Pyogenic tonsil remnants | 2 | Pain and scanty blood spots | 40 (Tranex, 500 mg/5 ml ampoules [2 times/day for 1 day; Malesci Istituto Farmacobiologico, Bagno a Ripoli, Italy], Contramal 100 mg capsules [1/day for a day; Formenti, Milan, Italy]) | 20 months/Complete recovery |
| 12 | 51 | Tonsillar hypertrophy and relapsing tonsillitis | 1 | Burning and pruritus | 20 (ice) | 18 months/ Complete recovery |
| 13 | 19 | Relapsing tonsillitis and laryngitis | 2 | Moderate discomfort and dryness | 15 (Ephynal 300 mg capsules [3 times/day for 2 weeks; Abiogen Pharma, Pisa, Italy] and ice) | 15 months/Improved symptoms |
| 14 | 63 | Post-viral tonsillar hypertrophy | 1 | / | 5 | 19 months/ Improved symptoms |
| 15 | 34 | Chronic tonsillitis | 1 | Moderate discomfort and cough | 20 (ice) | 12 months/Improved symptoms |
| 16 | 44 | Tonsillitis and tonsillar hypertrophy | 2 | / | 30 (Toradol 30 mg/ml ampoules [1/day for 2 days; Rome, Italy]) | 18 months/Complete recovery |
| 17 | 43 | Chronic fibrinous tonsillitis | 1 | Some transient dysphagia | 25 (ice) | 14 months/Improved symptoms but one replapsing episode was observed |
| 18 | 59 | Acute relapsing tonsillitis | 1 | Sore throat | 10 | 18 months/Complete recovery |
| 19 | 34 | Tonsillar hypertrophy and rheumatic fever | 1 | Slight oedema and swallowing burns | 25 (local Xentafid 0.13 % [3 times/day for 5 days; Fidia Farmaceutici, Abano Terme, Italy] and ice) | 24 months/Complete recovery |
| 20 | 21 | Waldeyer’s hypertrophy and tonsillar culture positive for Streptococcus viridians | 2 | Inflammation of the pharynx | 35 (Augmentin 375 mg tablets [2 times/day for 3 days; GlaxoSmithKline, Verona, Italy]) | 24 months/Improved symptoms but one replapsing episode was observed |
*Number of sessions varied according to the individual patient’s clinical situation
**Follow-up varied according to the individual patient’s clinical situation